[Form 4] Beta Bionics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Russell Steven Jon, identified as the Chief Medical Officer of Beta Bionics, Inc. (BBNX), reported a sale of 1,015 shares of the issuer's common stock on 09/02/2025. The filing states the sale was executed to cover tax withholding obligations tied to the vesting of restricted stock units. The weighted average sale price was $18.8632, with individual trade prices ranging from $18.58 to $19.09. After the transaction the reporting person beneficially owned 71,017 shares. The Form 4 was signed by an attorney-in-fact on 09/03/2025.

Positive

• Transaction disclosed as tax-withholding for RSU vesting, indicating routine and non-speculative insider activity
• Clear pricing detail provided: weighted average sale price $18.8632 and price range $18.58–$19.09
• Beneficial ownership reported after the sale (71,017 shares), maintaining transparency

Negative

• Reduction in holdings by 1,015 shares due to the sale
• Limited detail on quantity sold at each price; the filing states that full breakdown will be provided upon request

Insights

Financial Analyst

TL;DR: Routine insider sale to cover tax withholding; transaction size is small relative to total ownership and appears non-dispositive.

The sale of 1,015 shares at a weighted average price of $18.8632 is disclosed as tax-withholding related to RSU vesting, which is a common, non-speculative insider transaction. The residual beneficial ownership of 71,017 shares remains materially intact. There is no indication of accelerated sell-down or broader disposal program in the filing; impact on company capital structure or public float is negligible.

Corporate Governance Expert

TL;DR: Disclosure aligns with Section 16 reporting norms; use of attorney-in-fact signature is documented.

The Form 4 identifies the reporting person as the Chief Medical Officer and shows the form filed by one reporting person. The explanatory note specifies the shares were sold to satisfy tax withholding from RSU vesting, and the signature was executed by an attorney-in-fact on 09/03/2025. The filing meets standard transparency requirements and presents no governance red flags based on the information provided.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Russell Steven Jon

(Last) (First) (Middle)

C/O BETA BIONICS, INC.

11 HUGHES

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2025		S(1)		1,015	D	$18.8632(2)	71,017	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units.

2. The weighted average sale price for the transaction reported was $18.8632 and the range of prices were between $18.58 and $19.09. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

	/s/ Stephen Feider, Attorney-in-Fact	09/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Beta Bionics (BBNX) insider Russell Steven Jon sell on 09/02/2025?

The insider sold 1,015 common shares on 09/02/2025 to cover tax withholding obligations related to RSU vesting.

At what price were the BBNX shares sold in the Form 4 transaction?

The weighted average sale price was $18.8632, with individual trade prices ranging from $18.58 to $19.09.

How many BBNX shares does the reporting person own after the sale?

After the reported transaction the reporting person beneficially owned 71,017 shares.

Why were the BBNX shares sold according to the Form 4?

The filing states the shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units.

Who signed the Form 4 for this BBNX transaction?

The Form 4 was signed by Stephen Feider, Attorney-in-Fact on 09/03/2025.